Wellbutrin xl 150
IMPAX markets its generic products through its Global Pharmaceuticals division and intends to market its branded products through the IMPAX Pharmaceuticals division. Such statements are based on current expectations and involve a number of Wellbutrin xl 150 known and unknown risks and uncertainties that could cause IMPAX’s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Our actual results could differ materially Wellbutrin xl 150 from those discussed in, or implied by, these forward-looking statements. Biovail also filed suit in the United States District Court For The Southern District of Florida against Abrika Pharmaceuticals LLLP, which has submitted an ANDA for a generic 150mg version of Wellbutrin XL(R). District Court for the Southern District of Florida against GlaxoSmithKline plc and SmithKline Beecham Corporation (collectively "Glaxo"). Wellbutrin xl 150 about Biovail Corporation Biovail Corporation is an international full-service pharmaceutical company, engaged in the formulation, clinical testing, registration, manufacture, sale and promotion of pharmaceutical products utilizing advanced drug-delivery technologies. Biovail is responsible for the costs to manufacture the product. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties, including but not limited to, the timing and outcome of patent, antitrust and other litigation; the timing and scope of patents issued to our competitors; the FDA’s pending inspection; what sanctions, if any, FDA may seek following its decision to place us in OAI status, including without limitation sanctions relating to any failure to comply with cGMP requirements and if and when the "hold" on our ANDA approvals will be lifted; manufacturing capacities, safety issues, output and quality processes; our dependence on a relatively small number of products; future product launches; our ability to develop and successfully commercialize new products; the loss of revenues from existing products; licensing revenues; whether we will be awarded any marketing exclusivity period and, if so, the precise dates thereof; government regulation generally; competition; our ability to meet the supply and manufacturing requirements of the First Horizon agreement; the success of our joint ventures; recent management changes and the potential loss of senior management and other key personnel; and the absence of certainty regarding the receipt of required regulatory approvals or the timing or terms of such approvals. Wellbutrin xl 150 the patent estate protecting Wellbutrin XL(R) consists of two formulation patents (U. Food and Drug Administration ("FDA") and Canadian Therapeutic Products Directorate ("TPD") approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on wellbutrin xl 150 key strategic alliances, availability of raw materials and finished products, third parties, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission ("SEC") and the Ontario Securities Commission ("OSC"). Such risks and uncertainties include, but are not limited to, IMPAX’s ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, IMPAX’s ability to successfully develop and commercialize pharmaceutical products, IMPAX’s reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and other risks detailed from time to time in IMPAX’s filings with wellbutrin xl 150 the Securities and Exchange Commission. (NASDAQ:IPXL) today announced that Biovail Laboratories Inc. , a subsidiary of Biovail Corporation (NYSE:BVF) (TSX:BVF), has filed a lawsuit against the Company in the United States District Court, Eastern District of Pennsylvania (Philadelphia), alleging patent infringement related to IMPAX’s filing for a generic version of Wellbutrin XL(R). These Wellbutrin xl 150 two formulation patents expire in 2018. Patent numbers 6,143,327 and 6,096,341) listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations database (commonly referred to as the Orange Book). Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth Wellbutrin xl 150 in our 2004 10-K and in our other SEC filings. Forward-looking statements are identified by words such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and other similar expressions. We have based these forward-looking statements on our current expectations and projections about future events. Under the terms of the agreement, Biovail manufactures and supplies all wellbutrin xl 150 of GSK’s trade and sample supply requirements.